News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BIOTRONIK SE & Co.KG Announces ProMRI®Technology Extension for Full-Body MR Scans at ESC Congress 2013


8/29/2013 9:34:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERLIN, Germany, August 29, 2013—BIOTRONIK, a leading manufacturer of cardiovascular technology, today announced an extension of its ProMRI® technology. BIOTRONIK has combined advanced pacemaker and ICD technology with the option for patients to undergo MR scans. This makes BIOTRONIK the only company worldwide to allow ICD and heart failure patients (CRT-D and CRT-P) to take advantage of potentially life-saving MR scans. The new extension of ProMRI® technology means that even full-body scans are now available for pacemaker patients, placing BIOTRONIK’s implants firmly at the forefront of cardiac device innovation.

Thanks to BIOTRONIK´s Lumax 7, the Ilesto and Iforia ICDs/CRT-Ds, as well as the Evia HF-T, patients can have more than 88%1 of all required MR scans. Furthermore, patients implanted with the Evia single and dual chamber devices can now undergo 100% of all required scans, including liver and heart scans. BIOTRONIK received CE mark for its full-body scan ProMRI® technology with a backwards compatibility in mid August.

Each of BIOTRONIK’s cardiac devices are also equipped with BIOTRONIK’s Home Monitoring®, which rapidly detects deterioration in patients’ clinical status and automatically transmits data on a daily basis. This enables physicians to adapt patient therapy at a very early stage.

Late-breaking results from the BIOTRONIK IN-TIME Study, which evaluated the influence of implant-based BIOTRONIK Home Monitoring® on the clinical management of heart failure patients, will also be presented at the ESC Congress 2013 by Prof. Gerhard Hindricks, MD, Heart Center, University Leipzig, Germany, and discussed with Prof. Angelo Auricchio, Past President of the European Heart Rhythm Association (EHRA).

“Throughout our 50-year history, our goal has been to grant as many patients as possible access to leading-edge technology, ensuring the best therapies available”, explains Christoph Böhmer, President International at BIOTRONIK. “We’ve kept our promises to patients and physicians since our founding in 1963. Our technologies, like ProMRI® enabling full-body scans and BIOTRONIK Home Monitoring®, have proven our reliability, making a real difference in patients’ lives.”

Dates and places

Hot Line Session IN-TIME Study: Sunday, September 1st, 15.30, Room: Amsterdam - Central-Village BIOTRONIK booth: B315

About BIOTRONIK SE & Co. KG

As one of the world’s leading manufacturers of cardiovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million heart patients around the world have received BIOTRONIK implants, designed to save and improve the quality of their lives. Since its development of the first German pacemaker in 1963, BIOTRONIK has launched several innovations into the market—including remote monitoring with BIOTRONIK Home Monitoring® in 2000 and the world’s first implantable cardioverter-defibrillators and implantable heart failure therapy devices with ProMRI® technology, approved for MR scanning, in 2012. This year BIOTRONIK is celebrating its 50th anniversary.

For more information, visit: www.biotronik.com

References

1 Barmer Arzt report 2011

Contact:

Manuela Schildwächter

Global Communications Manager

BIOTRONIK SE & Co. KG

Woermannkehre 1

12359 Berlin

Tel. +49 (0) 30 68905 1466

Email: manuela.schildwaechter@biotronik.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES